Evaluation of ALSFRS-R Scale with Fuzzy Method in Amyotrophic Lateral Sclerosis

被引:0
|
作者
Koc, Gizem Gul [1 ]
Dagsuyu, Cansu [2 ]
Kokangul, Ali [1 ]
Koc, Filiz [3 ]
机构
[1] Cukurova Univ, Fac Engn, Dept Ind Engn, Adana, Turkey
[2] Alparslan Turkes Sci & Technol Univ, Fac Engn, Dept Ind Engn, Adana, Turkey
[3] Cukurova Univ, Dept Neurol, Fac Med, Adana, Turkey
来源
关键词
Amyotrophic lateral sclerosis; functional rating scale; fuzzy; FUNCTIONAL RATING-SCALE; TIME-SERIES; ADAPTATION; VALIDATION; RELIABILITY;
D O I
10.29399/npa.27449
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Amyotrophic lateral sclerosis (ALS) is a disease with high morbidity and mortality that adversely affects the activities of daily living. Disease progression in ALS is characterized by loss of function in bulbar, motor, and respiratory parameters. The revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R), which consists of 12 criteria, is used to determine disease effects on each of these functions. While each criterion is equally important when calculating the total ALSFRS-R score, the importance levels of the 12 criteria may vary in clinical practice. In this classical approach, the relationships among the parameters are not considered and the effects of bulbar, spinal, and respiratory dysfunctions on a patients activities of daily living may be different. Methods: In this study, we aimed to evaluate ALS cases with the ALSFRS- R fuzzy method. Although each subheading in the ALSFRS-R had the same score, the disease score was determined by the fuzzy ALSFRS-R method, based on whether a subheading had priority in management of the disease. While creating the functional rating scale ALSFRS-R approach, fuzzy ALSFRS-R score values were obtained by creating fuzzy models for each main group and integrating the fuzzy model results of each main group into a separate model. Results: In total, 50 patients with definite ALS according to the El Escorial criteria (33 men [66%] and 17 women [34%] mean age, 58.49 +/- 10.01 years) were included in the study. When ALSFRS-R results and fuzzy ALSFRS-R results were compared, the prioritization order of 45 patients increased using the fuzzy ALSFRS-R score, while the prioritization order of five patients remained the same in both evaluations. Conclusion: The approach obtained by using fuzzy membership functions and decision rules, formed in accordance with expert opinion, was applied to the data of 50 patients from a large-scale hospital. In total, 90% of the patients had increased prioritization when using the fuzzy ALSFRS-R scoring method. Our results showed that the fuzzy approach provided more accurate information regarding a patient's condition.
引用
收藏
页码:54 / 62
页数:9
相关论文
共 50 条
  • [21] Cumulative Distribution of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Scores in a Phase 3 Study of Edaravone (MCI-186) for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A Posthoc Assessment
    Takei, Koji
    Palumbo, Joseph M.
    Tsuda, Kikumi
    Liu, Shawn
    NEUROLOGY, 2017, 88
  • [22] Combinatory Biomarker Use of Cortical Thickness, MUNIX, and ALSFRS-R at Baseline and in Longitudinal Courses of Individual Patients With Amyotrophic Lateral Sclerosis
    Wirth, Anna M.
    Khomenko, Andrei
    Baldaranov, Dobri
    Kobor, Ines
    Hsam, Ohnmar
    Grimm, Thomas
    Johannesen, Siw
    Bruun, Pm-Henrik
    Schulte-Mattler, Wilhelm
    Greenlee, Mark W.
    Bogdahn, Ulrich
    FRONTIERS IN NEUROLOGY, 2018, 9
  • [23] Rate of Motor Unit Number Index (MUNIX) and ALSFRS-R decline over 21 months period in amyotrophic lateral sclerosis (ALS)
    Omer, T.
    Nasseroleslami, B.
    Molloy, F.
    Mullins, G.
    Hardiman, O.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 632 - 632
  • [24] Late-onset Patients with Sporadic Amyotrophic Lateral Sclerosis in Japan have a Higher Progression Rate of ALSFRS-R at the Time of Diagnosis
    Tanaka, Yuji
    Yoshikura, Nobuaki
    Harada, Naoko
    Yamada, Megumi
    Koumura, Akihiro
    Sakurai, Takeo
    Hayashi, Yuichi
    Kimura, Akio
    Hozumi, Isao
    Inuzuka, Takashi
    INTERNAL MEDICINE, 2012, 51 (06) : 579 - 584
  • [25] Performance of the amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials
    Cedarbaum, JM
    Stambler, N
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 152 : S1 - S9
  • [26] Validation of the Italian version of self-administered ALSFRS-R scale
    Manera, Umberto
    Cabras, Sara
    Daviddi, Margherita
    Vasta, Rosario
    Torrieri, Maria Claudia
    Palumbo, Francesca
    Bombaci, Alessandro
    Grassano, Maurizio
    Solero, Luca
    Peotta, Laura
    Iazzolino, Barbara
    Canosa, Antonio
    Calvo, Andrea
    Chio, Adriano
    Moglia, Cristina
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2021, 22 (1-2) : 151 - 153
  • [27] Development and evaluation of a self-administered version of the ALSFRS-R
    Montes, J.
    Levy, G.
    Albert, S.
    Kaufmann, P.
    Buchsbaum, R.
    Gordon, P. H.
    Mitsumoto, H.
    NEUROLOGY, 2006, 67 (07) : 1294 - 1296
  • [28] Diffusion tensor imaging in amyotrophic lateral sclerosis:: Relationships with the ALSFRS
    Thivard, L
    Lehéricy, S
    Pradat, PF
    Lacomblez, L
    Dormont, D
    Chiras, J
    Benali, H
    Meininger, V
    NEUROLOGY, 2004, 62 (07) : A279 - A279
  • [29] Do we really need to calculate a minimal important difference for ALSFRS-R?: A letter in response to 'Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R' published in Vol. 24(3-4), pp. 311-316
    Vazquez-Costa, Juan Francisco
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2024, 25 (1-2) : 214 - 215
  • [30] Do we really need to calculate a minimal important difference for ALSFRS-R?: A letter in response to Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R' published in Vol. 24(3-4), pp. 311-316
    Vazquez-Costa, Juan Francisco
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2023,